Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

Papatheodoridis G. V., Sypsa V., Dalekos G., Yurdaydin C., van Boemmel F., Buti M., ...More

JOURNAL OF HEPATOLOGY, vol.68, no.6, pp.1129-1136, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 68 Issue: 6
  • Publication Date: 2018
  • Doi Number: 10.1016/j.jhep.2018.01.031
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1129-1136
  • Hacettepe University Affiliated: Yes


Background & Aims: The effects of long-term antiviral therapy on survival have not been adequately assessed in chronic hepatitis B (CHB). In this 10-centre, ongoing cohort study, we evaluated the probability of survival and factors affecting survival in Caucasian CHB patients who received long-term entecavir/tenofovir therapy.